Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a major worldwide health problem. Recent studies suggest that the gut microbiota influences NAFLD pathogenesis. Here, a murine model of high-fat diet-induced (HFD-induced) NAFLD was used, and the effects of alterations in the gut microbiota on NAFLD were determined. Mice treated with antibiotics or tempol exhibited altered bile acid composition, with a notable increase in conjugated bile acid metabolites that inhibited intestinal farnesoid X receptor (FXR) signaling. Compared with control mice, animals with intestine-specific Fxr disruption had reduced hepatic triglyceride accumulation in response to a HFD. The decrease in hepatic triglyceride accumulation was mainly due to fewer circulating ceramides, which was in part the result of lower expression of ceramide synthesis genes. The reduction of ceramide levels in the ileum and serum in tempol- or antibiotic-treated mice fed a HFD resulted in downregulation of hepatic SREBP1C and decreased de novo lipogenesis. Administration of C16:0 ceramide to antibiotic-treated mice fed a HFD reversed hepatic steatosis. These studies demonstrate that inhibition of an intestinal FXR/ceramide axis mediates gut microbiota-associated NAFLD development, linking the microbiome, nuclear receptor signaling, and NAFLD. This work suggests that inhibition of intestinal FXR is a potential therapeutic target for NAFLD treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Hence, treatment with antibiotics ameliorates high-fat-diet-induced NAFLD in mice55.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [55]
In the citing paper
“Conversely, some data also indicate that antagonism of intestinal FXR signaling could improve metabolic parameters in murine models of NAFLD [256,257].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [257]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245
Functional interactions between the gut microbiota and host metabolism
Tremaroli, V., & Bäckhed, F. (2012) · Nature · doi:10.1038/nature11552 · Cited by 4,387
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829
Mechanisms underlying the resistance to diet-induced obesity in germ-free mice
Bäckhed, F., Manchester, J. K., Semenkovich, C. F., & Gordon, J. I. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605374104 · Cited by 2,615
Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.003 · Cited by 2,331
Human gut microbiota in obesity and after gastric bypass
Zhang, H., DiBaise, J. K., Zuccolo, A., Kudrna, D., Braidotti, M., Yu, Y., Parameswaran, P., Crowell, M. D., Wing, R., Rittmann, B. E., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812600106 · Cited by 1,880
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819 · cited 1×
“FXR, the central sensor and regulator for the biosynthesis and enterohepatic recycling of bile acids, plays a pivotal role in the control of lipid metabolism (42–45).”
Self-citation
Research works printed but not linked: 1
- 10.1172/jci21025 · DOI · Paper page
Cited by
Items 101–200 of 746
Liu, T.-C., Kern, J. T., Jain, U., Sonnek, N. M., Xiong, S., Simpson, K. F., VanDussen, K. L., Winkler, E. S., Haritunians, T., Malique, A., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.04.004 · Cited by 170
Intestinal Microbiota and Nonalcoholic Steatohepatitis
Brandl, K., & Schnabl, B. (2017) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000349 · Cited by 169
Sharpton, S. R., Ajmera, V., & Loomba, R. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.08.065 · Cited by 169
“Inhibition of intestinal FXR ameliorates high-fat diet–induced hepatic steatosis in murine models.(68) Recent preclinical studies have also supported a role for microbial alterations in bile acid metabolism, specifically an overabundance of deoxycholic acid (a secondary bile acid), in the development of obesity-relate…”
Sheng, L., Jena, P. K., Liu, H.-X., Kalanetra, K. M., Gonzalez, F. J., French, S. W., Krishnan, V. V., Mills, D. A., & Wan, Y.-J. Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-01576-9 · Cited by 155
Self-citationSex, gut microbiome, and cardiovascular disease risk
Razavi, A. C., Potts, K. S., Kelly, T. N., & Bazzano, L. (2019) · Biology of Sex Differences · doi:10.1186/s13293-019-0240-z · Cited by 169
Antibiotic effects on gut microbiota and metabolism are host dependent
Fujisaka, S., Ussar, S., Clish, C., Devkota, S., Dreyfuss, J. M., Sakaguchi, M., Soto, M., Konishi, M., Softic, S., Altindis, E., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86674 · Cited by 166
“Whereas FXR signaling is known to regulate bile acid (37) and lipid metabolism (38), the role of TGR5 is less clear.”
BackgroundThe role of bile acids in metabolic regulation
Vítek, L., & Haluzík, M. (2016) · Journal of Endocrinology · doi:10.1530/joe-15-0469 · Cited by 150
Di Ciaula, A., Baj, J., Garruti, G., Celano, G., De Angelis, M., Wang, H. H., Di Palo, D. M., Bonfrate, L., Wang, D. Q.-H., & Portincasa, P. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082648 · Cited by 163
Zhang, X., Zhang, Y., Wang, P., Zhang, S., Dong, Y., Zeng, G., Yan, Y., Sun, L., Wu, Q., Liu, H., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.016 · Cited by 163
Self-citationActivation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis
Xie, C., Yagai, T., Luo, Y., Liang, X., Chen, T., Wang, Q., Sun, D., Zhao, J., Ramakrishnan, S. K., Sun, L., et al. (2017) · Nature Medicine · doi:10.1038/nm.4412 · Cited by 161
Self-citationThe Role of the Gut Microbiota in Lipid and Lipoprotein Metabolism
Yu, Y., Raka, F., & Adeli, K. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122227 · Cited by 160
Current status, problems, and perspectives of non-alcoholic fatty liver disease research
Tanaka, N., Kimura, T., Fujimori, N., Nagaya, T., Komatsu, M., & Tanaka, E. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i2.163 · Cited by 138
Self-citationNonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
Ciaula, A. D., Passarella, S., Shanmugam, H., Noviello, M., Bonfrate, L., Wang, D. Q. ‐., & Portincasa, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105375 · Cited by 154
Zhou, M., Learned, R. M., Rossi, S. J., DePaoli, A. M., Tian, H., & Ling, L. (2017) · Hepatology Communications · doi:10.1002/hep4.1108 · Cited by 152
Cusi, K. (2016) · Diabetologia · doi:10.1007/s00125-016-3952-1 · Cited by 137
The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Chow, M. D., Lee, Y.-H., & Guo, G. L. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.04.004 · Cited by 140
Effect of different bile acids on the intestine through enterohepatic circulation based on FXR
Xiang, J., Zhang, Z., Xie, H., Zhang, C., Bai, Y., Cao, H., Che, Q., Guo, J., & Su, Z. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1949095 · Cited by 149
Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease
Suk, K. T., & Kim, D. J. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1569513 · Cited by 149
Microbiota, NASH, HCC and the potential role of probiotics
Brandi, G., De Lorenzo, S., Candela, M., Pantaleo, M. A., Bellentani, S., Tovoli, F., Saccoccio, G., & Biasco, G. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx007 · Cited by 142
Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet
Machado, M., & Cortez-Pinto, H. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040481 · Cited by 123
Contribution of specific ceramides to obesity-associated metabolic diseases
Hammerschmidt, P., & Brüning, J. C. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04401-3 · Cited by 143
Progress and challenges of selective Farnesoid X Receptor modulation
Massafra, V., Pellicciari, R., Gioiello, A., & van Mil, S. W. C. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.009 · Cited by 143
Wu, Q., Sun, L., Hu, X., Wang, X., Xu, F., Chen, B., Liang, X., Xia, J., Wang, P., Aibara, D., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142865 · Cited by 142
Self-citationIntestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut–liver axis
Han, H. L., Jiang, Y., Wang, M., Melaku, M., Liu, L., Zhao, Y. M., Everaert, N., Yi, B., & Zhang, H. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1966738 · Cited by 141
Yamada, S., Takashina, Y., Watanabe, M., Nagamine, R., Saito, Y., Kamada, N., & Saito, H. (2018) · Oncotarget · doi:10.18632/oncotarget.24066 · Cited by 129
Understanding bile acid signaling in diabetes: From pathophysiology to therapeutic targets
Ferrell, J. M., & Chiang, J. Y. L. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0043 · Cited by 139
Rodrigues, R. R., Greer, R. L., Dong, X., DSouza, K. N., Gurung, M., Wu, J. Y., Morgun, A., & Shulzhenko, N. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.02306 · Cited by 129
Pramfalk, C., Pavlides, M., Banerjee, R., McNeil, C. A., Neubauer, S., Karpe, F., & Hodson, L. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2649 · Cited by 138
“Additionally, we measured markers of cholesterol and bile acid metabolism as alterations in these have been implicated in NAFLD development (15, 16).”
MethodBaskin, A. S., Linderman, J. D., Brychta, R. J., McGehee, S., Anflick-Chames, E., Cero, C., Johnson, J. W., O’Mara, A. E., Fletcher, L. A., Leitner, B. P., et al. (2018) · Diabetes · doi:10.2337/db18-0462 · Cited by 138
Sheng, L., Jena, P. K., Hu, Y., Liu, H., Nagar, N., Kalanetra, K. M., French, S. W., French, S. W., Mills, D. A., & Wan, Y. Y. (2017) · The Journal of Pathology · doi:10.1002/path.4983 · Cited by 133
Ding, Y., Yanagi, K., Cheng, C., Alaniz, R. C., Lee, K., & Jayaraman, A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.029 · Cited by 126
García‐Lezana, T., Raurell, I., Bravo, M., Torres‐Arauz, M., Salcedo, M. T., Santiago, A., Schoenenberger, A., Manichanh, C., Genescà, J., Martell, M., et al. (2018) · Hepatology · doi:10.1002/hep.29646 · Cited by 136
Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease
Jiao, T., Ma, Y., Guo, X., Ye, Y., & Xie, C. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00880-z · Cited by 136
Self-citationGut commensal Christensenella minuta modulates host metabolism via acylated secondary bile acids
Liu, C., Du, M., Xie, L., Wang, W.-Z., Chen, B., Yun, C., Sun, X., Luo, X., Jiang, Y., Wang, K., et al. (2024) · Nature Microbiology · doi:10.1038/s41564-023-01570-0 · Cited by 136
Self-citationSheng, L., Jena, P. K., Liu, H., Hu, Y., Nagar, N., Bronner, D. N., Settles, M. L., Baümler, A. J., & Wan, Y. Y. (2018) · The FASEB Journal · doi:10.1096/fj.201800370r · Cited by 128
Fibroblast Growth Factor 15/19: From Basic Functions to Therapeutic Perspectives
Somm, E., & Jornayvaz, F. R. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00134 · Cited by 116
Farnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid Metabolism
Zhang, L., Xie, C., Nichols, R. G., Chan, S. H. J., Jiang, C., Hao, R., Smith, P. B., Cai, J., Simons, M. N., Hatzakis, E., et al. (2016) · mSystems · doi:10.1128/msystems.00070-16 · Cited by 126
Self-citationThe Gut–Liver Axis in the Control of Energy Metabolism and Food Intake in Animals
Ringseis, R., Geßner, D. K., & Eder, K. (2019) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-021419-083852 · Cited by 134
The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms
JASIRWAN, C. O. M., LESMANA, C. R. A., HASAN, I., SULAIMAN, A. S., & GANI, R. A. (2019) · Bioscience of Microbiota, Food and Health · doi:10.12938/bmfh.18-032 · Cited by 106
Shen, H., Zhou, L., Zhang, H., Yang, Y., Jiang, L., Wu, D., Shu, H., Zhang, H., Xie, L., Zhou, K., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.06.008 · Cited by 132
Tanaka, N., Takahashi, S., Zhang, Y., Krausz, K. W., Smith, P. B., Patterson, A. D., & Gonzalez, F. J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.02.012 · Cited by 120
Self-citationThe Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
Romero, F. A., Jones, C. T., Xu, Y., Fenaux, M., & Halcomb, R. L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01701 · Cited by 120
Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota
Doulberis, M., Kotronis, G., Gialamprinou, D., Kountouras, J., & Katsinelos, P. (2017) · Metabolism · doi:10.1016/j.metabol.2017.03.013 · Cited by 131
Xu, M., Cen, M., Shen, Y. S., Zhu, Y., Cheng, F., Tang, L., Hu, W., & Dai, N. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06208-3 · Cited by 127
Janssen, A. W. F., Houben, T., Katiraei, S., Dijk, W., Boutens, L., van der Bolt, N., Wang, Z., Brown, J. M., Hazen, S. L., Mandard, S., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m075713 · Cited by 122
Roles of Ceramides in Non-Alcoholic Fatty Liver Disease
Hajduch, É., Lachkar, F., Ferré, P., & Foufelle, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040792 · Cited by 126
Fatty liver diseases, bile acids, and FXR
Zhu, Y., Liu, H., Zhang, M., & Guo, G. L. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.07.008 · Cited by 118
Feng, S., Gan, L., Yang, C. S., Liu, A. B., Lu, W., Shao, P., Dai, Z., Sun, P., & Luo, Z. (2018) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.7b06146 · Cited by 123
The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD
Hong, T., Chen, Y., Li, X., & Lü, Y. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6889533 · Cited by 124
Caputo, T., Gilardi, F., & Desvergne, B. (2017) · FEBS Letters · doi:10.1002/1873-3468.12742 · Cited by 124
Nutritional modulation of gut microbiota — the impact on metabolic disease pathophysiology
Ojeda, P., Bobe, A., Dolan, K., Leone, V., & Martinez, K. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.08.013 · Cited by 105
Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation
Tian, Y., Cai, J., Gui, W., Nichols, R. G., Koo, I., Zhang, J., Anitha, M., & Patterson, A. D. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.083691 · Cited by 106
Self-citationRole of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease
Xi, Y., & Li, H. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109609 · Cited by 119
Depletion of gut microbiota induces skeletal muscle atrophy by FXR-FGF15/19 signalling
Qiu, Y., Yu, J., Li, Y., Yang, F., Yu, H., Xue, M., Zhang, F., Jiang, X., Ji, X., & Bao, Z. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.1900593 · Cited by 117
Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease
Mantovani, A., Ballestri, S., Lonardo, A., & Targher, G. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4040-6 · Cited by 116
Jena, P. K., Sheng, L., Liu, H., Kalanetra, K. M., Mirsoian, A., Murphy, W. J., French, S. W., Krishnan, V. V., Mills, D. A., & Wan, Y. Y. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.04.019 · Cited by 115
Moreno‐Navarrete, J. M., & Fernández‐Real, J. M. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09523-x · Cited by 117
Kasahara, K., Tanoue, T., Yamashita, T., Yodoi, K., Matsumoto, T., Emoto, T., Mizoguchi, T., Hayashi, T., Kitano, N., Sasaki, N., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m072165 · Cited by 107
Targeting FXR and FGF19 to Treat Metabolic Diseases—Lessons Learned From Bariatric Surgery
Bozadjieva, N., Heppner, K. M., & Seeley, R. J. (2018) · Diabetes · doi:10.2337/dbi17-0007 · Cited by 104
Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects
Legry, V., Francque, S., Haas, J. T., Verrijken, A., Caron, S., Chávez-Talavera, O., Vallez, E., Vonghia, L., Dirinck, E., Verhaegen, A., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01397 · Cited by 101
Yun, C., Yan, S., Liao, B., Ding, Y., Qi, X., Zhao, M., Wang, K., Zhuo, Y., Nie, Q., Ye, C., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01041-8 · Cited by 110
Self-citationZhang, C., Fang, R., Lu, X., Zhang, Y., Yang, M., Su, Y., Jiang, Y., & Man, C. (2022) · Food & Function · doi:10.1039/d1fo04387k · Cited by 110
Chiang, J. Y. L., Pathak, P., Liu, H., Donepudi, A., Ferrell, J., & Boehme, S. (2017) · Digestive Diseases · doi:10.1159/000450981 · Cited by 97
Sun, J., Fan, J., Li, T., Yan, X., & Jiang, Y. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c04817 · Cited by 106
An FGF15/19-TFEB regulatory loop controls hepatic cholesterol and bile acid homeostasis
Wang, Y., Gunewardena, S., Li, F., Matye, D. J., Chen, C., Chao, X., Jung, T., Zhang, Y., Czerwiński, M., Ni, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17363-6 · Cited by 105
Self-citationLau, L. H. S., & Wong, S. H. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-8684-7_9 · Cited by 105
Intestinal Farnesoid X Receptor Signaling Modulates Metabolic Disease
Gonzalez, F. J., Jiang, C., Xie, C., & Patterson, A. D. (2017) · Digestive Diseases · doi:10.1159/000450908 · Cited by 95
Self-citationHui, S., Liu, Y., Chen, M., Wang, X., Lang, H., Zhou, M., Yi, L., & Mi, M. (2019) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900608 · Cited by 103
Nonalcoholic Fatty Liver Disease and the Gut Microbiome
Boursier, J., & Diehl, A. M. (2015) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.012 · Cited by 102
Stanhope, K. L., Goran, M. I., Bosy‐Westphal, A., King, J. C., Schmidt, L. A., Schwarz, J. ‐., Stice, E., Sylvetsky, A. C., Turnbaugh, P. J., Bray, G. A., et al. (2018) · Obesity Reviews · doi:10.1111/obr.12699 · Cited by 87
The microbiota-gut-brain axis: Focus on the fundamental communication pathways
(2020) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2020.08.012 · Cited by 88
Hepatic Lipid Metabolism Disorder and Atherosclerosis
Zhang, S., Hong, F., Ma, C., & Yang, S. (2021) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666211220110810 · Cited by 98
The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease
Jennison, E., & Byrne, C. D. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0129 · Cited by 88
How did antibiotic growth promoters increase growth and feed efficiency in poultry?
Fernández-Miyakawa, M. E., Casanova, N. A., & Kogut, M. H. (2023) · Poultry Science · doi:10.1016/j.psj.2023.103278 · Cited by 99
Bile Acid Receptors and the Gut–Liver Axis in Nonalcoholic Fatty Liver Disease
Xue, R., Su, L., Lai, S., Wang, Y., Zhao, D., Fan, J., Chen, W., Hylemon, P. B., & Zhou, H. (2021) · Cells · doi:10.3390/cells10112806 · Cited by 95
“It also has been reported that intestinal specific knockout of FXR or selectively inhibits intestinal FXR improves NAFLD and obesity-related metabolic dysfunction [88,89].”
BackgroundRole of bile acids in carcinogenesis of pancreatic cancer: An old topic with new perspective
Feng, H., & Chen, Y. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i33.7463 · Cited by 94
Sphingolipid metabolism in non-alcoholic fatty liver diseases
Régnier, M., Polizzi, A., Guillou, H., & Loiseau, N. (2018) · Biochimie · doi:10.1016/j.biochi.2018.07.021 · Cited by 95
Recent advances on FXR-targeting therapeutics
Panzitt, K., Zollner, G., Marschall, H., & Wagner, M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111678 · Cited by 94
Gut microbiome determines therapeutic effects of OCA on NAFLD by modulating bile acid metabolism
Liu, J., Sun, J., Yu, J., Chen, H., Zhang, D., Zhang, T., Ma, Y., Zou, C., Zhang, Z., Ma, L., et al. (2023) · npj Biofilms and Microbiomes · doi:10.1038/s41522-023-00399-z · Cited by 94
Bluemel, S., Williams, B., Knight, R., & Schnabl, B. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00245.2016 · Cited by 83
The Gut Microbiome: Connecting Diet, Glucose Homeostasis, and Disease
Howard, E. J., Lam, T. K. T., & Duca, F. A. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042220-012821 · Cited by 94
Immunology of bile acids regulated receptors
Fiorucci, S., Marchianò, S., Urbani, G., Giorgio, C. D., Distrutti, E., Zampella, A., & Biagioli, M. (2024) · Progress in Lipid Research · doi:10.1016/j.plipres.2024.101291 · Cited by 92
Jayakumar, S., & Loomba, R. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15314 · Cited by 84
Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease
Li, T., & Chiang, J. Y. L. (2020) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2019.09.03 · Cited by 91
Radun, R., & Trauner, M. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1731707 · Cited by 80
Induction of farnesoid X receptor signaling in germ-free mice colonized with a human microbiota
Wahlström, A., Kovatcheva-Datchary, P., Ståhlman, M., Khan, M.-T., Bäckhed, F., & Marschall, H.-U. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m072819 · Cited by 84
He, X., Ji, G., Jia, W. P., & Li, H. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030300 · Cited by 91
Intrahepatic microbes govern liver immunity by programming NKT cells
Leinwand, J. C., Paul, B., Chen, R., Xu, F., Sierra, M. A., Paluru, M. M., Nanduri, S., Alcantara, C. G., Shadaloey, S. A. A., Yang, F., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci151725 · Cited by 76
Molecular basis of alcoholic fatty liver disease: From incidence to treatment
Lívero, F. A. D. R., & Acco, A. (2015) · Hepatology Research · doi:10.1111/hepr.12594 · Cited by 85
Gut microbiota, fatty liver disease, and hepatocellular carcinoma
Chu, H., Williams, B., & Schnabl, B. (2018) · Liver Research · doi:10.1016/j.livres.2017.11.005 · Cited by 84
Ducastel, S., Touche, V., Trabelsi, M.-S., Boulinguiez, A., Butruille, L., Nawrot, M., Peschard, S., Chávez-Talavera, O., Dorchies, E., Vallez, E., et al. (2020) · Scientific Reports · doi:10.1038/s41598-019-56743-x · Cited by 84
Gut microbes in metabolic disturbances. Promising role for therapeutic manipulations?
Portincasa, P., Khalil, M., Graziani, A., Frühbeck, G., Baffy, G., Garruti, G., Ciaula, A. D., & Bonfrate, L. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.10.002 · Cited by 84
Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches
Kim, K. H., & Lee, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00485 · Cited by 84
Adams, L. A., Wang, Z., Liddle, C., Melton, P. E., Ariff, A., Chandraratna, H. S., Tan, J. T. H., Ching, H. L., Coulter, S., de Boer, B., et al. (2020) · Liver International · doi:10.1111/liv.14453 · Cited by 82
Chronic liver disease enables gut Enterococcus faecalis colonization to promote liver carcinogenesis
Iida, N., Mizukoshi, E., Yamashita, T., Yutani, M., Seishima, J., Wang, Z., Arai, K., Okada, H., Yamashita, T., Sakai, Y., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00251-3 · Cited by 82
Role of bile acids in the regulation of the metabolic pathways
Taoka, H., Yokoyama, Y., Morimoto, K., Kitamura, N., Tanigaki, T., Takashina, Y., Tsubota, K., & Watanabe, M. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i13.260 · Cited by 80
Ballestri, S., Nascimbeni, F., Romagnoli, D., Baldelli, E., & Lonardo, A. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0306-9 · Cited by 80
Circulating microbiota-derived metabolites: a “liquid biopsy?
Aragonès, G., Colom-Pellicer, M., Aguilar, C., Guiu-Jurado, E., Martínez, S., Sabench, F., Antonio Porras, J., Riesco, D., Del Castillo, D., Richart, C., et al. (2020) · International Journal of Obesity · doi:10.1038/s41366-019-0430-0 · Cited by 69
Xu, G., & Song, M. (2020) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2020.08.028 · Cited by 82
Zhou, S., You, H., Qiu, S., Yu, D., Bai, Y., He, J., Cao, H., Che, Q., Guo, J., & Su, Z. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113577 · Cited by 80
Metadata
- Authors
- Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R. G., Krausz, K. W., Cai, J., Qi, Y., Fang, Z.-Z., Takahashi, S., Tanaka, N., Desai, D., Amin, S. G., Albert, I., Patterson, A. D., & Gonzalez, F. J.
- Affiliations
- National Institutes of Health (US)
- Pennsylvania State University (US)
- Corresponding author
- Patterson, Andrew D.
- Gonzalez, Frank J.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-12-15
- Volume
- 125
- Issue
- 1
- Pages
- 386-402
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4382255
- OpenAlex
- W2124025733
- Cited by
- 693
- References
- 68
- Citations by year
- 2026: 43 · 2025: 52 · 2024: 52 · 2023: 61 · 2022: 76 · 2021: 84 · 2020: 70 · 2019: 63 · 2018: 58 · 2017: 61 · 2016: 46 · 2015: 26
- FWCI
- 33.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Environmental Health Sciences (R01ES022186, ES022186)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- non-alcoholic fatty liver disease, gut microbiota, bile acids, bile acid conjugates, ceramide, ceramide synthesis, SREBP-1c, de novo lipogenesis, hepatic steatosis, high-fat diet, antibiotic therapy, tempol, nuclear receptor signaling, therapeutic target
- MeSH terms
- Receptor, Farnesoid X-Activated, Animals, Anti-Bacterial Agents, Bile Acids and Salts, Cecum, Gene Expression Regulation, Humans, Ileum, Liver, Male, Mice, Inbred C57BL, Mice, Transgenic, Gene Expression, Receptors, Cytoplasmic and Nuclear, Lipid Metabolism, Metabolic Networks and Pathways, Diet, High-Fat, Mitochondrial Dynamics, Microbiota, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.